Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Preparedness

RFI – Vaccine Candidates and Technologies for Filoviruses

by Global Biodefense Staff
August 18, 2015

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking information from pharmaceutical and biopharmaceutical product developers on multivalent vaccines and rapidly adaptable vaccine platform technologies against filoviruses such as Ebola and Marburg.

The primary focus of this RFI is to gather information about multivalent filovirus vaccine candidates that at a minimum have shown efficacy in nonhuman primate disease models for at least one of the filovirus components.

NIAID is emphasizing interest in any multivalent filovirus vaccine candidates that incorporates technological enhancements, such as the following:

  • Vaccine presentations or formulations that are stable without the need for cold chain
  • Rapid onset of protective immunity that will permit a prophylaxis indication in a post-event scenario
  • Minimal doses to achieve protection
  • Reasonable complexity of vaccine components
  • Non-parenteral routes of delivery
  • Needle-free delivery
  • Addressing issues such as anti-vector immunity and vaccine interference
  • Maturity of immune assays that may be used to identify correlates of protection

Multivalent filovirus vaccine candidates that also incorporate a component to confer protection against Lassa Fever are of also noted to be of interest.

Further details are available via Solicitation Number: NOT-AI-15-049. The response deadline is September 4, 2015.

Tags: EbolaLassa FeverMarburgRFIThermostabilityVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Predictive Intelligence for Pandemic Prevention Grant Awarded to Virginia Tech Researchers
Preparedness

Predictive Intelligence for Pandemic Prevention Grant Awarded to Virginia Tech Researchers

October 25, 2022
dressed head to toe in protective suit and gloves, a worker places a dropper of liquid onto a small plastic device to test for Ebola virus
Outbreak News

How Prepared is Uganda for the Current Ebola Outbreak?

September 24, 2022
A Treaty to Break the Pandemic Cycle: Don’t Ignore Key Lessons from the Past Two Years
Policy + Initiatives

A Treaty to Break the Pandemic Cycle: Don’t Ignore Key Lessons from the Past Two Years

July 16, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy